CEL-SCI Corp(CVM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CVM CEL-SCI Corp

Trading 12-23 12:44:37 EST

0.7127

-0.0172

-2.36%

High0.8135	Low0.7000	Vol402.73K
Open0.8135	D1 Closing0.7299	Amplitude15.55%
Mkt Cap45.48M	Tradable Cap44.19M	Total Shares63.81M
T/O300.22K	T/O Rate0.65%	Tradable Shares62.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CVM","market":"US","secType":"STK","nameCN":"CEL-SCI Corp","latestPrice":0.7127,"timestamp":1734975740958,"preClose":0.7299,"halted":0,"volume":402733,"delay":0,"floatShares":62001133,"shares":63807104,"eps":-0.578914,"marketStatus":"Trading","change":-0.0172,"latestTime":"12-23 12:44:37 EST","open":0.8135,"high":0.8135,"low":0.7,"amount":300217.1940301,"amplitude":0.155501,"askPrice":0.7273,"askSize":100,"bidPrice":0.7,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.578914,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1734987600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":433828800000,"exchange":"AMEX","adjPreClose":0.7299,"preHourTrading":{"tag":"盘前","latestPrice":0.812,"preClose":0.7299,"latestTime":"09:29 EST","volume":6105,"amount":4651.28381025,"timestamp":1734964187506},"postHourTrading":{"tag":"盘后","latestPrice":0.7748,"preClose":0.7299,"latestTime":"19:53 EST","volume":5777,"amount":4266.1588,"timestamp":1734742436082},"volumeRatio":0.327721,"impliedVol":0.3479,"impliedVolPercentile":0.0159},"requestUrl":"/m/hq/s/CVM/wiki","defaultTab":"wiki","newsList":[{"id":"2492410922","title":"Amex Halt  Add Info Lst 0.840000","url":"https://stock-news.laohu8.com/highlight/detail?id=2492410922","media":"THOMSON REUTERS","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492410922?lang=en_us&edition=fundamental","pubTime":"2024-12-20 01:12","pubTimestamp":1734628379,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241219:nAQN2JUUSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVM","BK4139"],"gpt_icon":0},{"id":"2491936844","title":"Innocan Pharma Provides its Annual \"State of Research and Development\" Update for 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2491936844","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491936844?lang=en_us&edition=fundamental","pubTime":"2024-12-13 05:01","pubTimestamp":1734037260,"startTime":"0","endTime":"0","summary":"HERZLIYA, Israel and CALGARY, Alberta, Dec. 12, 2024 /CNW/ -- Innocan Pharma Corporation     a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and an owner of a proprietary intellectual property portfolio, is pleased to share its annual \"State of Research and Development\" update for 2024. This year, the Company achieved significant milestones in advancing research and development for its drug delivery platforms as well as its intellectual property portfolio.During 2024, Innocan achieved significant milestones in both scientific and regulatory domains. Preclinical studies of its liposome-cannabidiol technology (LPT-CBD( demonstrated high CBD bioavailability, along with long-lasting pain relief and improved well-being in various animal models. Building on this compelling data, the Company secured agreement from the United States Food and Drug Administration (FDA) on the preclinical and Phase 1 clinical development plan to advance LP","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0E.7l4y9jnds4XLTwEXGMQ--~B/aD0yODM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0E.7l4y9jnds4XLTwEXGMQ--~B/aD0yODM7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/7706f970d25ba77672f989a1db7cd166"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innocan-pharma-provides-annual-state-210100474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4557","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4588","ACB","LU1883839398.USD","IE00B3QW5Z07.USD","INN","BK4139","BK4181","STT","BK4135","LU0061475181.USD","INNPF","CVM","IE0034235188.USD","BK4218","BK4585","BK4007"],"gpt_icon":0},{"id":"2490879633","title":"CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2490879633","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490879633?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:15","pubTimestamp":1734012900,"startTime":"0","endTime":"0","summary":"Multikine is the first cancer immunotherapy to show pre-surgical tumor regression in head and neck cancer in just 3 weeks - confirmed by pathology at surgery. Factors supporting the go-ahead for the 212-person registration study in the target population include:. Multikine led to significant rates of tumor regression. Pre-surgical tumor regressions were confirmed at surgery and forecast survival benefit. Target population is likely to show significant survival prolongation in the confirmatory study. Confirmatory study target population selection is based on:. Strong statistical significance in a large subgroup of 114 patients. Strong biological rationale for the results based on Multikine’s mechanism of action . The Phase 3 study missed the primary endpoint of 10% improvement in overall survival  in the ITT population  but showed a 46.5-month  OS benefit vs control  in the patients who received Multikine followed by surgery and radiotherapy. In the other group","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8BmWiXx5HRLEXXBZF8uK2Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/51c62ce853d0e3d5dff54cee0a1524f8","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8BmWiXx5HRLEXXBZF8uK2Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/51c62ce853d0e3d5dff54cee0a1524f8"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cel-sci-highlights-biological-rationale-141500652.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0054578231.USD","LU0053671581.USD","OS","BK4585","SAP","BK4139","BK4097","ITT","BK4528","BK4161","CVM","BK4588","CEL","BK4023"],"gpt_icon":0},{"id":"2490502776","title":"CVM: CRO Selected for Registrational Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490502776","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490502776?lang=en_us&edition=fundamental","pubTime":"2024-12-09 17:39","pubTimestamp":1733737140,"startTime":"0","endTime":"0","summary":"CEL-SCI Corporation  has made progress advancing the prerequisites for the upcoming registrational trial, selecting the contract research organization  that will run it and coming to an agreement with the FDA on which biomarkers are appropriate for selecting patients. The view of oncologists as expressed by the FDA’s ODAC is that using checkpoint inhibitors to treat low PD-L1 expressing patients provides limited efficacy and could even be harmful. This view opens the door for the use of Multikine, if approved, in the low expressing PD-L1 patient population based on its efficacy in this group.FDA ODAC opines against use of checkpoints in low PD-L1 expression patients – October 2024. FDA agrees to use of PD-L1 biomarker in Multikine registration study – November 2024. The 79 patients who were recommended to receive only radiotherapy benefited to an even greater degree from pre-surgery treatment with Multikine compared to the wider 114 patient group. This target low risk population  had a","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cvm-cro-selected-registrational-trial-093900095.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["OS","BK4097","BK4192","PET","CVM","BK4139"],"gpt_icon":0},{"id":"2483753404","title":"BRIEF-Cel-Sci Corp Says On November 13, Patricia B Prichep Has Assumed The Duties Of Chief Financial And Operations Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483753404","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483753404?lang=en_us&edition=fundamental","pubTime":"2024-11-16 07:04","pubTimestamp":1731711848,"startTime":"0","endTime":"0","summary":"BRIEF-Cel-Sci Corp Says On November 13, Patricia B Prichep Has Assumed The Duties Of Chief Financial And Operations OfficerNov 15  - CEL-SCI Corp CVM.A:CEL-SCI CORP: ON NOVEMBER 13, PATRICIA B PRICHEP HAS ASSUMED THE DUTIES OF CHIEF FINANCIAL AND OPERATIONS OFFICERSource text: [ID:n0001654954-24-014554]Further company coverage: CVM.A ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nFWN3MM18X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVM","BK4139"],"gpt_icon":0},{"id":"2483533711","title":"CEL-SCI Corp: on November 13, Patricia B Prichep Has Assumed the Duties of Chief Financial and Operations Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2483533711","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483533711?lang=en_us&edition=fundamental","pubTime":"2024-11-16 05:33","pubTimestamp":1731706438,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241115:nFWN3MM18X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVM","BK4139"],"gpt_icon":0},{"id":"2482304709","title":"BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482304709","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482304709?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:30","pubTimestamp":1731414600,"startTime":"0","endTime":"0","summary":"- Patients on acoramidis, a near complete (≥90%) TTR stabilizer in clinical development, lived longer and better as shown in the ATTRibute-CM study. This is the only Phase 3 study of an ATTR-CM diseas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2978984/0/en/BridgeBio-Pharma-Reports-Third-Quarter-2024-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CVM"],"gpt_icon":0},{"id":"2482630997","title":"Innocan to Direct Full Focus on Following Positive FDA Engagement and Significant Potential Market Demand","url":"https://stock-news.laohu8.com/highlight/detail?id=2482630997","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482630997?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:01","pubTimestamp":1731358860,"startTime":"0","endTime":"0","summary":"A recent National Pet Owners Survey demonstrates a significant addressable market for Innocan's veterinary product. Innocan has received FDA support to advance its LPT-CBD platform for human use under the 505 abbreviated pathway, offering a quicker route to commercial approval. The FDA has also aligned on Innocan's non-clinical development plan and Phase I clinical study design for the LPT-CBD's Investigational New Drug  filing, moving the Company closer to an accelerated approval process. Furthermore, it is noted that Innocan has made strong progress with the FDA's Center for Veterinary Medicine  with the issuance of an Investigational New Animal Drug  designation in July.Following the positive response of the FDA regarding the LPT-CBT product reported in September 2024, as well as the continued progress of the LPT-CBD project and significant addressable market potential for LPT-CBD, Innocan has decided to shift its focus and resources in its pharmaceutical division to the LPT-CBD pro","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innocan-direct-full-focus-following-210100841.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4018","BK4218","BK4533","CLX","ACB","BK4585","LU1571399168.USD","BK4532","INNPF","CVM","BK4557","INN","BK4007","BK4139","BK4181","BK4588","BK4567","BK4504"],"gpt_icon":0},{"id":"2481135830","title":"CEL-SCI, FDA agree on Phase 3 trial design for cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2481135830","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481135830?lang=en_us&edition=fundamental","pubTime":"2024-11-08 00:31","pubTimestamp":1730997090,"startTime":"0","endTime":"0","summary":"hapabapa CEL-SCI Corporation (NYSE:CVM) announced Thursday that the FDA agreed to its proposal to use the PD-L1 biomarker status in selecting patients for a registrational trial for its lead cancer therapy, Multikine. Accordingly, the 212-subject confirmatory trial is expected to enroll newly","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413289936/image_1413289936.jpg?io=getty-c-w750","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1413289936/image_1413289936.jpg?io=getty-c-w750"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4261655-cel-sci-fda-agree-multikine-trial-design","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha_trending_news","symbols":["CVM","CEL","BK4139"],"gpt_icon":0},{"id":"2481904795","title":"U.S. FDA and CEL-SCI Agree on Use of Pd-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904795","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904795?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:17","pubTimestamp":1730985448,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241107:nFWN3ME0ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CVM","BK4139"],"gpt_icon":0},{"id":"2481226902","title":"U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2481226902","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481226902?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:15","pubTimestamp":1730985300,"startTime":"0","endTime":"0","summary":"Biomarker used to select patients who are more likely have favorable outcomes, supporting a successful confirmatory Registration Study. \"To our knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population. This underscores the critical importance of having reached an agreement with the FDA on the method for identifying and selecting patients with low PD-L1 tumor expression for our upcoming confirmatory Registration study,\" stated CEL-SCI CEO Geert Kersten.CEL-SCI believes that boosting a patient’s immune system while it is still intact should provide the greatest possible impact on survival. Multiki","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/pMk2IkM1C.llWeYfb0ZgFA--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a281976e7754b0b2f5a56aebabbe7471","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/pMk2IkM1C.llWeYfb0ZgFA--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/a281976e7754b0b2f5a56aebabbe7471"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/u-fda-cel-sci-agree-131500730.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","SLCT","LU1169589451.USD","LU1169590202.USD","CEL","BK4080","CVM","ADC","BK4023","BK4231","PD"],"gpt_icon":0},{"id":"2481668503","title":"Press Release: GERDAU S.A. - CONSOLIDATED INFORMATION","url":"https://stock-news.laohu8.com/highlight/detail?id=2481668503","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481668503?lang=en_us&edition=fundamental","pubTime":"2024-11-06 06:35","pubTimestamp":1730846100,"startTime":"0","endTime":"0","summary":"SO PAULO, Nov. 5, 2024 /PRNewswire/ -- 3Q24 Highlights. Adjusted EBITDA  of R$ 3.0 billion in the third quarter, 14.9% higher compared to 2Q24.Investments  totaled R$ 1.5 billion in 3Q24, of which R$ 589 million was allocated to Maintenance and R$ 920 million was directed to the Competitiveness of the Business Divisions.Dividend distribution in the amount of R$ 0.30 per share, equivalent to R$ 619,4 million, to be paid based on 3Q24 results.Share buyback program of Gerdau S.A., by the end of October 2024, 39.6 million shares were repurchased, equivalent to R$ 729.4 million.The 3Q24 Valuation Guide is also available at Gerdau's website.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CVM","BK4115","CNSL","LU0532187761.SGD","IE00B1B80R65.USD","III","BK4139","GGB","BK4134","BK4006","LU0210535034.USD"],"gpt_icon":0},{"id":"2481566213","title":"Press Release: ITAÚ UNIBANCO - Projections","url":"https://stock-news.laohu8.com/highlight/detail?id=2481566213","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481566213?lang=en_us&edition=fundamental","pubTime":"2024-11-05 06:39","pubTimestamp":1730759940,"startTime":"0","endTime":"0","summary":"SO PAULO, Nov. 4, 2024 /PRNewswire/ -- Itaú Unibanco Holding S.A. , in compliance with the provisions in Article 157, paragraph 4 of Law No. 6,404/76 and in Resolution No. 44/21 of the Brazilian Securities and Exchange Commission , informs its stockholders and the market in general that it released as of this date its revised projections for the year 2024 in accordance with item 3  of the Reference Form.with clients          4.5% and 7.5%        5.5% and 8.5%. fees and results      5.0% and 8.0%        5.5% and 8.5%. Composed of results from loan losses, impairment and discounts granted; . Commissions and fees (+) income from insurance, pension plan and premium bonds. operations (-) expenses for claims (-) insurance, pension plan and premium. bonds selling expenses;  Considers pro forma adjustments in 2023 of the. sale of Banco Itaú Argentina;  Core expenses below inflation.It is important to mention that since July/24 the company has been considering a cost of capital of around 14.0% ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0106259046.USD","LU0456842615.SGD","LU0050427557.USD","ITUB","IE00B1B80R65.USD","LU0788109048.HKD","BK4139","LU0128526570.USD","LU0072463663.USD","LU0256859116.SGD","LU0229945570.USD","LU0265266980.USD","LU0543330566.HKD","LU0228659784.USD","BK4207","LU0572108347.SGD","ITA","LU0320763518.SGD","IE00B0JY6N72.USD","LU0532187761.SGD","LU0029865408.USD","CVM","BK4585","BK4588"],"gpt_icon":0},{"id":"2479745580","title":"Solana News: Canary Capital Files for New ETF, What’s Next for SOL Price?","url":"https://stock-news.laohu8.com/highlight/detail?id=2479745580","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479745580?lang=en_us&edition=fundamental","pubTime":"2024-10-31 11:14","pubTimestamp":1730344483,"startTime":"0","endTime":"0","summary":"Amid the growing Solana  dominance in the web3 space, Canary Capital, an investment management firm founded by Steven McClurg who is one of the founding team of Valkyrie Funds, has filed with the United States Securities and Exchange Commission  to offer its spot ETF. Filed on Wednesday, October 30, the Canary Solana ETF aims to provide institutional investors with a secure and highly liquid gateway to investing in one of the fast-growing altcoins.Canary Capital has aggressively doubled down on its focus in the altcoin market despite the low traction registered with the Spot Ether ETFs. Already, the firm has filed for a spot Litecoin  ETF and spot XRP ETF, which may be approved next year. The firm’s first altcoin offering was the Canary HBAR Trust, which ensures institutional investors have access to the growing Hedera network.From a technical analysis standpoint, SOL price must consistently close above the macro falling logarithmic trend and also July’s peak to invalidate potential sh","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/dc9cd3289fb94751860465538b7aa1a4.webp","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/dc9cd3289fb94751860465538b7aa1a4.webp"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/6722f623a1d0a9668b6168a4/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["BK4139","BK4129","CVM","AVAX.USD.HKCC","FDN","BK4519","LTC.USD.HKCC","BK4585","SOL","LTC","BK4588","BK4550","BK4225","BK4203"],"gpt_icon":0},{"id":"2478226962","title":"CEL-SCI Corp Files Prospectus Relates to Possible Resale, From Time to Time, by Selling Shareholder of up to 1 Mln Shares of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2478226962","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478226962?lang=en_us&edition=fundamental","pubTime":"2024-10-26 05:22","pubTimestamp":1729891331,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241025:nFWN3M11ZO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CVM"],"gpt_icon":0},{"id":"2478596226","title":"CEL-SCI files to sell 1M shares of common stock for holders","url":"https://stock-news.laohu8.com/highlight/detail?id=2478596226","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478596226?lang=en_us&edition=fundamental","pubTime":"2024-10-26 05:20","pubTimestamp":1729891211,"startTime":"0","endTime":"0","summary":"17:19 EDT CEL-SCI (CVM) files to sell 1M shares of common stock for holders Published first on TheFly – the ultimate source for real-time, market-m...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cel-sci-files-to-sell-1m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cel-sci-files-to-sell-1m-shares-of-common-stock-for-holders?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CEL","CVM","BK4139"],"gpt_icon":0},{"id":"2477332514","title":"FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 Negative Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2477332514","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477332514?lang=en_us&edition=fundamental","pubTime":"2024-10-22 21:15","pubTimestamp":1729602900,"startTime":"0","endTime":"0","summary":"Oncologic Drugs Advisory Committee  determines risks outweigh benefits in some cancers for frontline immune checkpoint inhibitors, including blockbuster drugs such as Keytruda and Opdivo, in patients with low PD-L1 expression. Multikine has shown survival benefit and favorable safety profile in a randomized controlled Phase 3 study of treatment nave resectable locally advanced head and neck cancer patients with low PD-L1 expression. Multikine has potential as a combination drug with current checkpoint inhibitors such as Keytruda which is projected to be the top selling drug in the world with $27 billion in 2024 sales. To the Company’s knowledge, Multikine is the only neoadjuvant immunotherapy that has shown overall survival benefit in the low and negative PD-L1 head and neck cancer population. adequacy of PD-L1 expression as a predictive biomarker for patient selection in this patient population. Checkpoint inhibitors were an estimated $48 billion global market in 2023, with PD-L1 inhi","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/2cMFE6Y8OdmiWGLN6YYx9Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e52d47d398d1381d2ccf4197bc36c388","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/2cMFE6Y8OdmiWGLN6YYx9Q--~B/aD0yNDA7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/e52d47d398d1381d2ccf4197bc36c388"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-oncologic-drugs-advisory-committee-131500707.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1917777945.USD","LU0266013472.USD","LU1061106388.HKD","CEL","LU1116320901.HKD","IE00BBT3K403.USD","IE00BJT1NW94.SGD","CVM","LU1934455277.USD","LU1066051811.HKD","LU0238689110.USD","BK4023","LU1066051225.USD","LU0965509101.SGD","LU1430594728.SGD","LU0965509010.AUD","IE00BJJMRZ35.SGD","LU1093756325.SGD","LU0265550946.USD","LU0320765489.SGD","BK4585","IE00B1BXHZ80.USD","LU0211331839.USD","LU1023059063.AUD","BK4533","LU0965509283.SGD","LU0234572021.USD","LU0965508806.USD","IE00BN8TJ469.HKD","LU0985320562.USD","MRK","LU0861579265.USD","LU1941712264.USD","LU1169589451.USD","LU1934455194.USD","LU1585245621.USD","LU1093756168.USD","IE00B2B36J28.USD","LU1066051498.USD","LU0203347892.USD","BK4550","IE0002141913.USD","IE00B4R5TH58.HKD","LU1057294990.SGD","PD","BK4139","LU1116320737.USD","BK4588","IE00BLSP4239.USD","LU1934455863.HKD"],"gpt_icon":0},{"id":"2475340645","title":"Brazil’s Central Bank Digital Currency Unveils Drex Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2475340645","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475340645?lang=en_us&edition=fundamental","pubTime":"2024-10-15 06:14","pubTimestamp":1728944063,"startTime":"0","endTime":"0","summary":"The Central Bank of Brazil has officially opened its doors to participants for the Drex Project, the nation’s venture into developing a digital version of the Brazilian Central Bank Digital Currency . Drex will enhance the nation’s financial infrastructure by introducing tokenized currency options. Interestingly, the project is a significant step toward positioning Brazil as a digital currency-friendly country.The bank has emphasized that participants are expected to engage in experiments while focusing on fostering privacy solutions for digital currency transactions. Given the increasing concerns about data privacy and cybersecurity in digital finance, the Drex project aims to create a secure and privacy-conscious system for its users.The registration portal for the Drex Project is now open and will remain accessible until November 29, 2024. Participants are encouraged to collaborate to shape the future of digital currency in Brazil. Through experimentation and innovation, the project","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/0aaf32894b0b478a9816ad4bba459f33.jpeg","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/0aaf32894b0b478a9816ad4bba459f33.jpeg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/670d97c201b42e6b3775447e/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["FDN","BK4585","BK4550","CVM","BK4139","BK4588"],"gpt_icon":0},{"id":"2474104265","title":"Innocan Pharma's LPT-CBD Shows Long-Term Success in Relieving Osteoarthritis Pain in Dogs","url":"https://stock-news.laohu8.com/highlight/detail?id=2474104265","media":"CNW Group","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2474104265?lang=en_us&edition=fundamental","pubTime":"2024-10-12 04:01","pubTimestamp":1728676860,"startTime":"0","endTime":"0","summary":"HERZLIYA, Israel and CALGARY, Alberta, Oct. 11, 2024 /CNW/ -- InnocanPharma Corporation    , a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce promising results from a multi-year compassionate therapy using repeated liposomal-CBD  injections for pain relief in dogs with naturally-occurring osteoarthritis. The therapy consistently demonstrated pain reduction and improved mobility, with effects lasting for several weeks after each injection as expected. These results further demonstrate that LPT-CBD can be a viable treatment option for managing chronic pain and enhancing the quality of life in animals.In two ongoing cases, dogs suffering from osteoarthritis who were treated with LPT-CBD after failing to respond to non-steroidal anti-inflammatory drugs  and oral CBD, showed noticeable pain relief, substantially improved mobility and increased, clearly noticeable well-being. Both dogs remained on LPT-CBD treatment for 2 and 2.5 years respectively after th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/KJLSIxEyVP4G61TXboPO4Q--~B/aD0xNzg7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/8b2fd4dbe4ed1dd3719ec221a12ddb50"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/innocan-pharmas-lpt-cbd-shows-200100251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CBD","LPT","ACB","INNPF","INN","CVM","BK4218","BK4139","BK4007","BK4181","BK4557","BK4113"],"gpt_icon":0},{"id":"2472377355","title":"Embark on the Conflux Tech Odyssey: Mapping Out the Next 3–5 Years!","url":"https://stock-news.laohu8.com/highlight/detail?id=2472377355","media":"CoinMarketCap","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2472377355?lang=en_us&edition=fundamental","pubTime":"2024-10-01 22:45","pubTimestamp":1727793951,"startTime":"0","endTime":"0","summary":"As we conclude Q3 and enter the year’s final stretch, we are thrilled to present our tech roadmap for the coming years. From enhanced blockchain solutions to pioneering AI integrations, our roadmap is","market":"us","thumbnail":"https://academy-public.coinmarketcap.com/srd-optimized-uploads/f3bdc35432c143518d3ff81f61d6d803.jpg","type":0,"news_type":0,"thumbnails":["https://academy-public.coinmarketcap.com/srd-optimized-uploads/f3bdc35432c143518d3ff81f61d6d803.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://coinmarketcap.com/community/articles/66fc0b200802537439c98f33/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"coinmarketcap_highlight","symbols":["LU0300736492.USD","MPC","LU0788109394.HKD","LU0368265418.SGD","BK4099","BK4139","BK4585","LU0300736062.USD","BK4534","LU0170899867.USD","BK4588","IE00BSNM7G36.USD","BK4554","AMT","BK4138","LU0456854461.SGD","LU0122376428.USD","BK4581","LU0266512127.USD","BK4219","BK4084","CVM","300750"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.cel-sci.com","stockEarnings":[{"period":"1week","weight":0.0578},{"period":"1month","weight":0.1623},{"period":"3month","weight":-0.3242},{"period":"6month","weight":-0.4342},{"period":"1year","weight":-0.7266},{"period":"ytd","weight":-0.7317}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research, development, and manufacturing of immune systems for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, a Leukocyte Interleukin injection, which has completed a pivotal Phase 3 clinical trial for patients, who are diagnosed with locally advanced primary squamous cell carcinoma of the head and neck. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company is developing CEL-2000 and CEL-4000 which are LEAPS based product candidates for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.","yearOnYearQuotes":[{"month":1,"riseRate":0.658537,"avgChangeRate":0.174507},{"month":2,"riseRate":0.317073,"avgChangeRate":0.019413},{"month":3,"riseRate":0.365854,"avgChangeRate":-0.024897},{"month":4,"riseRate":0.560976,"avgChangeRate":0.120775},{"month":5,"riseRate":0.268293,"avgChangeRate":-0.005038},{"month":6,"riseRate":0.390244,"avgChangeRate":0.004075},{"month":7,"riseRate":0.170732,"avgChangeRate":-0.065723},{"month":8,"riseRate":0.341463,"avgChangeRate":0.034264},{"month":9,"riseRate":0.365854,"avgChangeRate":0.050328},{"month":10,"riseRate":0.317073,"avgChangeRate":-0.073657},{"month":11,"riseRate":0.390244,"avgChangeRate":0.010993},{"month":12,"riseRate":0.317073,"avgChangeRate":0.006437}],"exchange":"AMEX","name":"CEL-SCI Corp","nameEN":"CEL-SCI Corp"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"CEL-SCI Corp(CVM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest CEL-SCI Corp(CVM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"CEL-SCI Corp,CVM,CEL-SCI Corp股票,CEL-SCI Corp股票老虎,CEL-SCI Corp股票老虎国际,CEL-SCI Corp行情,CEL-SCI Corp股票行情,CEL-SCI Corp股价,CEL-SCI Corp股市,CEL-SCI Corp股票价格,CEL-SCI Corp股票交易,CEL-SCI Corp股票购买,CEL-SCI Corp股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"CEL-SCI Corp(CVM),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest CEL-SCI Corp(CVM) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}